The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
The real-world evidence Flatiron's record system collects "is a key ingredient to accelerate the development of, and access to, new cancer treatments."
